SCHEDULE: Cochlear Maintains 5.91% Stake in Nyxoah SA

Cochlear Investments Pty Ltd and its parent Cochlear Limited have filed an amendment to their Schedule 13D, confirming their beneficial ownership of 5,847,283 ordinary shares in Nyxoah SA, representing 5.91% of the outstanding shares.

Summary

• This filing is an amendment (Amendment No. 5) to a previously filed Schedule 13D concerning Nyxoah SA.
• The reporting persons are Cochlear Investments Pty Ltd and its parent company, Cochlear Limited.
• As of the filing date, Cochlear Investments directly owns 5,847,283 ordinary shares of Nyxoah SA.
• This holding represents 5.91% of the outstanding ordinary shares of Nyxoah SA.
• Cochlear Limited may be deemed to indirectly beneficially own these shares due to its parent-subsidiary relationship with Cochlear Investments.
• The total number of outstanding ordinary shares of Nyxoah SA is stated as 98,894,961, based on a prospectus supplement filed on June 5, 2026.
• The reporting persons have not acquired any additional shares or effected any transactions in the past 60 days.
• The reporting persons do not have the right to acquire any additional ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update to confirm existing ownership levels without new information on transactions or strategic shifts.

Positives

• Cochlear Limited maintains a significant minority stake (5.91%) in Nyxoah SA, indicating continued strategic interest or investment.
• The reporting persons have not engaged in any recent transactions, suggesting a stable holding period.

Negatives

• The filing does not report any new acquisitions or increases in stake, implying no immediate expansion of ownership by Cochlear.

Risks

• The filing does not explicitly mention any new risks or challenges.
• Potential future changes in Nyxoah SA's performance or strategic direction could impact the value of Cochlear's investment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the reporting persons regarding their future intentions with Nyxoah SA, beyond maintaining their current stake.

Industry Context

StockSavvy.ai notes that this Schedule 13D amendment from Cochlear Limited confirms its substantial minority interest in Nyxoah SA, a company focused on neurostimulation for conditions like sleep apnea. This ongoing stake suggests a continued strategic alignment or investment thesis by Cochlear in Nyxoah's technology and market potential within the medical device sector.

Stakeholder Impact

• Shareholders of Nyxoah SA: The confirmation of Cochlear's stable 5.91% stake may provide some reassurance of continued institutional interest, but it does not signal a change in control or a potential takeover.
• Shareholders of Cochlear Limited: This filing confirms the ongoing investment in Nyxoah SA, the financial implications of which are tied to Nyxoah's future performance.
• Regulators (SEC): Ensures compliance with disclosure requirements for significant beneficial ownership.

Next Steps

• The reporting persons will continue to monitor their investment in Nyxoah SA.
• Future amendments to Schedule 13D will be filed if there are material changes in beneficial ownership or intentions.

Key Dates

Keywords

Nyxoah SA, Cochlear Limited, Cochlear Investments Pty Ltd, Schedule 13D, Beneficial Ownership, Ordinary Shares, SEC Filing, Amendment, Shareholder